Q4 2012 · —
Revenue$33.00K$33.00K no prior Q4 2011 on file−2.9% vs Q3 2012
Net income—
EPS Diluted-$2.08-$2.08 no prior Q4 2011 on fileN/M vs Q3 2012
Operating Income-$4,238,000—
Operating Cash Flowderived-$3,976,000—
Free Cash Flowderived-$3,976,000—
Margins · derived
Operating margin-12842.4%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q4 2011 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR